Literature DB >> 17265013

[Adenosine for treatment of ischemic pain in thromboangiitis obliterans. A case report].

Philip M Lang1, D Irnich.   

Abstract

Treating ischemic pain is often unsatisfactory. Current findings demonstrate that patients with chronic ischemia may develop sensory neuropathy and signs of central sensitization. This issue makes is reasonable treating with conventional analgesics and drugs against neuropathic pain. Adenosine has also a pain reducing effect in neuropathic pain which makes it a possible therapeutic option in ischemic pain.We report of a patient with thromboangiitis obliterans. We treated his pain with a broad analgesic therapy and administered adenosine intravenously, which resulted in a reduction of pain for several hours. Afterwards the patient received buflomedil to increase adenosine plasma levels. A long term pain reduction could be achieved. Modulation of adenosine demonstrates an experimental approach in the therapy of ischemic pain in thromboangiitis obliterans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17265013     DOI: 10.1007/s00482-007-0528-5

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  19 in total

1.  Activation of adenosine and P2Y receptors by ATP in human peripheral nerve.

Authors:  Philip M Lang; David J Tracey; Dominik Irnich; Wolfgang Sippel; Peter Grafe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-06       Impact factor: 3.000

2.  Systemic adenosine infusions alleviated neuropathic pain.

Authors:  Eva Gyllenhammar; Lars-Olof Nordfors
Journal:  Pain       Date:  2001-10       Impact factor: 6.961

3.  Sensory neuropathy and signs of central sensitization in patients with peripheral arterial disease.

Authors:  Philip M Lang; Gabriel M Schober; Roman Rolke; Susanne Wagner; Robert Hilge; Martin Offenbächer; Rolf-Detlef Treede; Ulrich Hoffmann; Dominik Irnich
Journal:  Pain       Date:  2006-05-22       Impact factor: 6.961

4.  Adenosine and neuropathic pain.

Authors:  R Guieu; J C Peragut; P Roussel; H Hassani; F Sampieri; G Bechis; R Gola; H Rochat
Journal:  Pain       Date:  1996-12       Impact factor: 6.961

5.  Observations on the algogenic actions of adenosine compounds on the human blister base preparation.

Authors:  Tirza Bleehen; C A Keele
Journal:  Pain       Date:  1977-08       Impact factor: 6.961

6.  Systemic adenosine infusion alleviates spontaneous and stimulus evoked pain in patients with peripheral neuropathic pain.

Authors:  M Belfrage; A Sollevi; M Segerdahl; K F Sjölund; P Hansson
Journal:  Anesth Analg       Date:  1995-10       Impact factor: 5.108

7.  The influence of adenosine, ketamine, and morphine on experimentally induced ischemic pain in healthy volunteers.

Authors:  M Segerdahl; A Ekblom; A Sollevi
Journal:  Anesth Analg       Date:  1994-10       Impact factor: 5.108

8.  Dose response of intrathecal adenosine in experimental pain and allodynia.

Authors:  James C Eisenach; Regina Curry; David D Hood
Journal:  Anesthesiology       Date:  2002-10       Impact factor: 7.892

Review 9.  Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases.

Authors:  S P Clissold; S Lynch; E M Sorkin
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

10.  Lumbar neurolytic sympathetic blockades provide immediate and long-lasting improvement of painless walking distance and muscle metabolism in patients with severe peripheral vascular disease.

Authors:  M Gleim; C Maier; U Melchert
Journal:  J Pain Symptom Manage       Date:  1995-02       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.